Former Athira CEO addresses controversy and departure in letter to employees

In a letter to employees, former Athira Pharma CEO Leen Kawas said she regrets that mistakes she made at Washington State University caused a distraction to the company. In the letter, which has been obtained by the Business Journal, Kawas admitted to enhancing images in her doctoral research but denied that she manipulated or changed the data. She added that her research didn't involve Athira's (Nasdaq: ATHA) current lead drug candidate, ATH-1017. "It is my hop e that by stepping aside, I am helping…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news